HDAC6 and neoplasm: These data confirm that R306465 is a specific inhibitor of HDAC1/3 in A2780 tumour cells, which is in contrast to other HDAC inhibitors in clinical development that are more potent towards HDAC6 (e.g. vorinostat) or have a broader spectrum of activity (e.g. panobinostat).